Codex will pay $10M upfront for license.

Codexis obtained a licese to use Dyadic International’s C1 expression system for large-scale production of enzymes in certain fields including biofuels and chemical and pharmaceutical intermediate production. The agreement includes an upfront payment by Codexis of $10 million provided that certain performance criteria are satisfied.

“Codexis develops improved biocatalysts, which are solving specific industrial challenges for global leaders in pharmaceuticals and bioindustrials. We are developing advanced biofuels from nonfood biomass sources, and we have other programs aimed at addressing critical environmental issues,” said Alan Shaw, Ph.D., Codexis president and CEO. “The Dyadic production system expands our technology platform, providing improved capability and efficiency in enzyme production across many Codexis programs.”

Previous articlePharmaleads to Assist with Development of Debiopharm’s Chronic Pain Therapeutic
Next articleNew Cell Damage Clue Provided in Huntington’s Disease